Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.


Clinical Trial Description

The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.

A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.

Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.

The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00708175
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 4
Start date May 2008
Completion date February 2011

See also
  Status Clinical Trial Phase
Recruiting NCT00973336 - Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery? Phase 2
Completed NCT04203212 - BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH
Not yet recruiting NCT06182852 - The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus
Completed NCT01773304 - Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile N/A
Withdrawn NCT00853502 - The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Phase 2
Completed NCT01183299 - Salty Life 7 Study: Effect of High Salt Intake on Several Physiological Systems in Immobilisation N/A